Entera Bio (ENTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $2.77, +10.80% vs the prior close of $2.50.
- Volume 1.45M shares, 3.1x its 50-day average (heavy).
- New SEC filings: DEF 14A (Oct 14, 2026).
- No new insider buys or sales reported since the prior session.
ENTX jumps 10.8% to $2.77 on 3.1x normal volume. Closed at $2.77, +10.80% vs the prior close of $2.50. Day range $2.49–$2.82, opened at $2.49.
ENTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ENTX jumps 10.8% to $2.77 on 3.1x normal volume
- Closed at $2.77, +10.80% vs the prior close of $2.50. Day range $2.49–$2.82, opened at $2.49.
- Volume was 1.45M shares, 3.1x its 50-day average of 462.18K — unusually heavy trading.
- Price is -4.0% vs its 50-day average ($2.88) and +50.9% vs its 200-day average ($1.84).
- 52-week range $0.91–$4.20; today's close sits at 57% of that range, 34.0% below the 52-week high.
Oct 14, 2026 — ENTX rises 0.4% to $2.50
- Closed at $2.50, +0.40% vs the prior close of $2.49. Day range $2.46–$2.57, opened at $2.47.
- Volume was 784.50K shares, 1.7x its 50-day average of 463.32K.
- Price is -13.4% vs its 50-day average ($2.89) and +36.6% vs its 200-day average ($1.83).
- 52-week range $0.91–$4.20; today's close sits at 48% of that range, 40.5% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 13, 2026 — ENTX slides 6.0% to $2.49, a 1-month low
- Closed at $2.49, -6.04% vs the prior close of $2.65. Day range $2.43–$2.65, opened at $2.65.
- Volume was 755.00K shares, 1.6x its 50-day average of 470.27K.
- Price is -13.9% vs its 50-day average ($2.89) and +36.3% vs its 200-day average ($1.83).
- 52-week range $0.91–$4.20; today's close sits at 48% of that range, 40.7% below the 52-week high.
Oct 12, 2026 — ENTX dips 0.4% to $2.65
- Closed at $2.65, -0.38% vs the prior close of $2.66. Day range $2.64–$2.78, opened at $2.66.
- Volume was 305.40K shares, 0.6x its 50-day average of 485.36K.
- Price is -8.7% vs its 50-day average ($2.90) and +45.4% vs its 200-day average ($1.82).
- 52-week range $0.91–$4.20; today's close sits at 53% of that range, 36.9% below the 52-week high.
Oct 9, 2026 — ENTX jumps 6.4% to $2.66 on 3.3x normal volume
- Closed at $2.66, +6.40% vs the prior close of $2.50. Day range $2.51–$2.72, opened at $2.51.
- Volume was 1.58M shares, 3.3x its 50-day average of 481.52K — unusually heavy trading.
- Price is -8.6% vs its 50-day average ($2.91) and +46.3% vs its 200-day average ($1.82).
- 52-week range $0.91–$4.20; today's close sits at 53% of that range, 36.7% below the 52-week high.
Oct 8, 2026 — ENTX dips 0.4% to $2.50, a 1-month low, 6 down days in a row
- Closed at $2.50, -0.40% vs the prior close of $2.51. Day range $2.45–$2.52, opened at $2.48.
- Volume was 421.00K shares, 0.8x its 50-day average of 504.67K.
- Price is -14.2% vs its 50-day average ($2.91) and +37.8% vs its 200-day average ($1.81).
- 52-week range $0.91–$4.20; today's close sits at 48% of that range, 40.5% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — ENTX dips 0.8% to $2.51, a 1-month low, 5 down days in a row
- Closed at $2.51, -0.79% vs the prior close of $2.53. Day range $2.45–$2.58, opened at $2.52.
- Volume was 679.50K shares, 1.1x its 50-day average of 597.55K.
- Price is -14.2% vs its 50-day average ($2.92) and +38.6% vs its 200-day average ($1.81).
- 52-week range $0.91–$4.20; today's close sits at 49% of that range, 40.2% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — ENTX slides 3.4% to $2.53, a 1-month low, 4 down days in a row
- Closed at $2.53, -3.44% vs the prior close of $2.62. Day range $2.53–$2.67, opened at $2.66.
- Volume was 621.20K shares, 0.3x its 50-day average of 2.25M — lighter than usual.
- Price is -13.9% vs its 50-day average ($2.94) and +39.9% vs its 200-day average ($1.81).
- 52-week range $0.91–$4.20; today's close sits at 49% of that range, 39.8% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 5, 2026 — ENTX slides 8.4% to $2.62, a 1-month low, 3 down days in a row
- Closed at $2.62, -8.39% vs the prior close of $2.86. Day range $2.62–$2.89, opened at $2.89.
- Volume was 1.25M shares, 0.6x its 50-day average of 2.23M — lighter than usual.
- Price is -11.7% vs its 50-day average ($2.97) and +45.2% vs its 200-day average ($1.81).
- 52-week range $0.91–$4.20; today's close sits at 52% of that range, 37.6% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — ENTX dips 1.0% to $2.86
- Closed at $2.86, -1.04% vs the prior close of $2.89. Day range $2.82–$2.90, opened at $2.89.
- Volume was 100.70K shares, 0.0x its 50-day average of 2.23M — lighter than usual.
- Price is -3.3% vs its 50-day average ($2.96) and +58.7% vs its 200-day average ($1.80).
- 52-week range $0.91–$4.20; today's close sits at 59% of that range, 31.9% below the 52-week high.
ENTX latest news & SEC filings
Every SEC filing by or about ENTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 23, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 28, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 28, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 21, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 21, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Things to know before you trade ENTX
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 8, 2026, Mar 27, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.00% (largest 10.8%).
- Liquidity: about 634.02K shares (≈$1.76M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $2.77 vs a range of $0.91–$4.20 (57% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Geno J Germano bought 20,000 shares on Mar 9, 2026.
- Latest filings: 8-K Oct 6, 2026; 8-K Aug 18, 2026; 10-Q Aug 7, 2026.
- Share count: 173.14M shares outstanding (Aug 3, 2026), +279.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ENTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 2.49 | 2.82 | 2.49 | 2.77 | 1.45M |
| Oct 14, 2026 | 2.47 | 2.57 | 2.46 | 2.50 | 784.50K |
| Oct 13, 2026 | 2.65 | 2.65 | 2.43 | 2.49 | 755.00K |
| Oct 12, 2026 | 2.66 | 2.78 | 2.64 | 2.65 | 305.40K |
| Oct 9, 2026 | 2.51 | 2.72 | 2.51 | 2.66 | 1.58M |
| Oct 8, 2026 | 2.48 | 2.52 | 2.45 | 2.50 | 421.00K |
| Oct 7, 2026 | 2.52 | 2.58 | 2.45 | 2.51 | 679.50K |
| Oct 6, 2026 | 2.66 | 2.67 | 2.53 | 2.53 | 621.20K |
| Oct 5, 2026 | 2.89 | 2.89 | 2.62 | 2.62 | 1.25M |
| Oct 2, 2026 | 2.89 | 2.90 | 2.82 | 2.86 | 100.70K |
| Oct 1, 2026 | 2.89 | 3.00 | 2.81 | 2.89 | 640.80K |
| Sep 30, 2026 | 2.67 | 2.97 | 2.57 | 2.91 | 520.60K |
| Sep 29, 2026 | 2.70 | 2.72 | 2.66 | 2.69 | 160.80K |
| Sep 28, 2026 | 2.80 | 2.89 | 2.64 | 2.69 | 340.90K |
| Sep 25, 2026 | 2.91 | 2.91 | 2.70 | 2.74 | 775.20K |
| Sep 24, 2026 | 2.78 | 2.88 | 2.71 | 2.80 | 233.80K |
| Sep 23, 2026 | 3.01 | 3.01 | 2.70 | 2.81 | 858.10K |
| Sep 22, 2026 | 3.02 | 3.03 | 2.94 | 2.98 | 613.60K |
| Sep 21, 2026 | 2.93 | 2.97 | 2.86 | 2.96 | 294.70K |
| Sep 18, 2026 | 3.14 | 3.14 | 2.88 | 2.96 | 289.00K |
About Entera Bio
Entera Bio (ENTX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in JERUSALEM. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1638097.
ENTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Sean Ellis | Director | Aug 7, 2026 |
| Geno J Germano | Director | Aug 7, 2026 |
| Gerald M Lieberman | Director | Jan 2, 2026 |
| Yonatan Malca | Director | Aug 7, 2026 |
| Gerald M Ostrov | Director | Jan 2, 2026 |
| Steven D Rubin | Director | Aug 7, 2026 |
| Haya Taitel | Director | Aug 7, 2026 |
| Miranda Jayne Toledano | Chief Executive Officer | Aug 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gregory Burshtein | Chief of R&D | Aug 7, 2026 |
| Riccardo Paolo Camisasca | Chief Medical Officer | Aug 21, 2026 |
| Hillel Galitzer | Chief Operating Officer | Aug 7, 2026 |
| Miranda Jayne Toledano | Chief Executive Officer | Aug 7, 2026 |
| Dana Yaacov-Garbeli | Chief Financial Officer | Aug 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 9, 2026 | Geno J Germano | Buy | 20,000 | $1.30 |
| Mar 5, 2026 | Sean Ellis | Buy | 10,000 | $1.23 |
| Feb 12, 2026 | Steven D Rubin | Buy | 5,000 | $1.49 |
| Feb 10, 2026 | Haya Taitel | Buy | 7,500 | $1.48 |
| Feb 10, 2026 | Geno J Germano | Buy | 20,000 | $1.49 |
| Feb 9, 2026 | Steven D Rubin | Buy | 10,000 | $1.20 |
| Feb 9, 2026 | Sean Ellis | Buy | 18,000 | $1.24 |
| Dec 29, 2025 | Miranda Jayne Toledano | Buy | 11,000 | $1.81 |
ENTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $42.00K | $-11.44M | 0.25 | $-7.37M |
| Dec 31, 2024 | $181.00K | $-9.54M | 0.25 | $-6.82M |
| Dec 31, 2023 | $0 | $-8.89M | 0.31 | $-7.31M |
| Dec 31, 2022 | $134.00K | $-13.07M | 0.45 | $-12.50M |
| Dec 31, 2021 | $571.00K | $-12.19M | 0.47 | $-9.06M |
Latest balance sheet: total assets $19.48M, total liabilities $12.21M, cash $11.31M (as of Jun 30, 2026).
ENTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | $2.87 |
| May 8, 2026 | 8-K Item 2.02 (results) | $1.30 |
| Mar 27, 2026 | 8-K Item 2.02 (results) | $1.13 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $2.71 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $1.82 |
| May 9, 2025 | 8-K Item 2.02 (results) | $2.15 |
| Mar 28, 2025 | 8-K Item 2.02 (results) | $1.75 |
| Nov 8, 2024 | 8-K Item 2.02 (results) | $1.72 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ENTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.